Who makes Intraviteal Ranibizumab 0.5mg?

Intraviteal Ranibizumab 0.5mg is developed by Nagoya City University.

What development phase is Intraviteal Ranibizumab 0.5mg in?

Intraviteal Ranibizumab 0.5mg is FDA-approved (marketed).

Last reviewed 2026-05-14 · How we verify

Intraviteal Ranibizumab 0.5mg

Nagoya City University · FDA-approved active Small molecule Quality 1/100

At a glance

Generic name	Intraviteal Ranibizumab 0.5mg
Sponsor	Nagoya City University
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular AMD. (PHASE4)
Evaluation of the Usefulness of a PRN Regimen Using Ranibizumab for Macular Edema Due to Branch Retinal Vein Occlusion (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Intraviteal Ranibizumab 0.5mg CI brief — competitive landscape report
Intraviteal Ranibizumab 0.5mg updates RSS · CI watch RSS
Nagoya City University portfolio CI